Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?
- PMID: 33139607
- PMCID: PMC7693493
- DOI: 10.3390/nu12113363
Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?
Abstract
Diet and lifestyle interventions are the recommended treatment for patients with non-alcoholic fatty liver disease (NAFLD), with the aim of achieving a 7-10% weight loss. Several dietary patterns have been suggested for this purpose, however, to date, the best one is represented by the Mediterranean diet (MD) as it is rich in macro- and micro- nutrients known for their effectiveness in health-promotion and cardio-vascular disease prevention. Moreover, MD is characterized by the inclusion of nuts. These foods have shown potential benefits in health-promotion as they are rich in fibers, which have lipid-lowering effects, rich in mono- and poly-unsaturated fatty acids, which help reduce insulin-resistance and serum cholesterol, and contain anti-oxidants which reduce oxidative stress and inflammation. Additionally, nuts are associated with a better control, or reduction, of Body Mass Index (BMI). All these effects are useful targets to achieve in NAFLD, so that nuts have been proposed as a suitable dietary treatment supplement for weight and metabolic control in these patients. In recent years, health authorities raised an alert on nuts consumption as these may be at high risk of aflatoxin (AF) contamination, for which controls and legislations are different among countries. AF is a well-known cancerogenic agent and a recognized risk factor for hepatocellular carcinoma. Patients with NAFLD have an overall, inherent sevenfold increased risk of developing hepatocellular carcinoma as compared with the general population. In this context, one could argue that recommending the inclusion of nuts in the diet of NAFLD patients has to be balanced with the risk of potential chronic exposure to AF, and every effort should be pursued to assure the safety of these nutrients. In this review, we aim to summarize the benefits of nuts consumption, the evidence for AF contamination of nuts and the consequent potential risks in patients with NAFLD.
Keywords: aflatoxin; hepatocellular carcinoma; liver disease; peanuts; steatohepatitis; steatosis.
Conflict of interest statement
M.C.P.T., G.B., E.M., M.F., P.Z. have no conflict of interest to declare. E.G.G. reports advisory boards for M.S.D. and Eisai, Shionogi, Bayer, AbbVie, Gilead Sciences.
Figures
Similar articles
-
Treatment of NAFLD with diet, physical activity and exercise.J Hepatol. 2017 Oct;67(4):829-846. doi: 10.1016/j.jhep.2017.05.016. Epub 2017 May 23. J Hepatol. 2017. PMID: 28545937 Review.
-
The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms.Liver Int. 2017 Jul;37(7):936-949. doi: 10.1111/liv.13435. Epub 2017 Jun 1. Liver Int. 2017. PMID: 28371239 Review.
-
Mediterranean diet and non-alcoholic fatty liver disease: new therapeutic option around the corner?World J Gastroenterol. 2014 Jun 21;20(23):7339-46. doi: 10.3748/wjg.v20.i23.7339. World J Gastroenterol. 2014. PMID: 24966604 Free PMC article. Review.
-
Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults.Adv Nutr. 2018 Jan 1;9(1):30-40. doi: 10.1093/advances/nmx007. Adv Nutr. 2018. PMID: 29438460 Free PMC article. Review.
-
Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet.World J Gastroenterol. 2014 Dec 7;20(45):16831-40. doi: 10.3748/wjg.v20.i45.16831. World J Gastroenterol. 2014. PMID: 25492997 Free PMC article. Review.
Cited by
-
SntB triggers the antioxidant pathways to regulate development and aflatoxin biosynthesis in Aspergillus flavus.Elife. 2024 Nov 5;13:RP94743. doi: 10.7554/eLife.94743. Elife. 2024. PMID: 39499647 Free PMC article.
-
Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC.Biomedicines. 2021 Oct 23;9(11):1524. doi: 10.3390/biomedicines9111524. Biomedicines. 2021. PMID: 34829753 Free PMC article. Review.
-
Nutrient patterns and risk of diabetes mellitus type 2: a case-control study.BMC Endocr Disord. 2024 Jan 17;24(1):10. doi: 10.1186/s12902-024-01540-5. BMC Endocr Disord. 2024. PMID: 38229053 Free PMC article.
-
Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances.Eur J Med Res. 2024 Oct 5;29(1):485. doi: 10.1186/s40001-024-02072-3. Eur J Med Res. 2024. PMID: 39367507 Free PMC article. Review.
-
Therapeutic Effects of Crocin Alone or in Combination with Sorafenib against Hepatocellular Carcinoma: In Vivo & In Vitro Insights.Antioxidants (Basel). 2022 Aug 25;11(9):1645. doi: 10.3390/antiox11091645. Antioxidants (Basel). 2022. PMID: 36139719 Free PMC article.
References
-
- Singh S., Allen A.M., Wang Z., Prokop L.J., Murad M.H., Loomba R. Fibrosis progression in nonalcoholic fatty liver vs. nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clin. Gastroenterol. Hepatol. 2015;13:643–654.e9. doi: 10.1016/j.cgh.2014.04.014. - DOI - PMC - PubMed
-
- European Association for the Study of the Liver. European Association for the Study of Diabetes. European Association for the Study of Obesity EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59:1121–1140. doi: 10.1007/s00125-016-3902-y. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
